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Abstract
We questioned if acute administration of n-3 fatty acids (FA) carried in n-3 rich triglyceride (TG) emulsions provides
neuroprotection in neonatal mice subjected to hypoxic-ischemic (H/I) brain injury. We examined specificity of FA, optimal
doses, and therapeutic windows for neuroprotection after H/I. H/I insult was induced in C57BL/6J 10-day-old mice by right
carotid artery ligation followed by exposure to 8% O2 for 15 minutes at 37uC. Intraperitoneal injection with n-3-rich TG
emulsions, n-6 rich TG emulsions or saline for control was administered at different time points before and/or after H/I. In
separate experiments, dose responses were determined with TG containing only docosahexaenoic acid (Tri-DHA) or
eicosapentaenoic acid (Tri-EPA) with a range of 0.1–0.375 g n-3 TG/kg, administered immediately after H/I insult. Infarct
volume and cerebral blood flow (CBF) were measured. Treatment with n-3 TG emulsions both before- and after- H/I
significantly reduced total infarct volume by a mean of 43% when administered 90 min prior to H/I and by 47% when
administered immediately after H/I. In post-H/I experiments Tri-DHA, but not Tri-EPA exhibited neuroprotective effects with
both low and high doses (p,0.05). Moreover, delayed post-H/I treatment with Tri-DHA significantly decreased total infarct
volume by a mean of 51% when administered at 0 hr, by 46% at 1 hr, and by 51% at 2 hr after H/I insult. No protective
effect occurred with Tri-DHA injection at 4 hr after H/I. There were no n-3 TG related differences in CBF. A significant
reduction in brain tissue death was maintained after Tri-DHA injection at 8 wk after the initial brain injury. Thus, n-3 TG,
specifically containing DHA, is protective against H/I induced brain infarction when administered up to 2 hr after H/I injury.
Acute administration of TG-rich DHA may prove effective for treatment of stroke in humans.
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Introduction
Stroke is the third major cause of death in adults in the United
States, after coronary heart disease and cancer. It is estimated that
in the USA stroke-related medical costs and disability were
approximately $73.7 billion in 2010 [1]. In addition, with an
estimated incidence of 1 in 2300 to 5000 births, stroke is more
likely to occur in the perinatal period than at other times in
childhood [2]. Ischemic stroke in neonates is a disorder associated
with significant long-term neurologic morbidity [2]. Twenty to
60% of survivors exhibit long-term detrimental neuropsycholog-
ical consequences which include mental retardation, cerebral
palsy, and behavioral disorders [2].
Multiple mechanisms are associated with neuronal damage in
ischemic stroke. Abnormalities of cerebral blood flow (CBF) can
result in metabolic responses such as increased anaerobic
metabolism, and biochemical responses such as increased excit-
atory amino acids, intracellular accumulation of calcium, activa-
tion of nitric oxide synthesis, and production of free radicals.
These mechanisms occur over a range of time, with early events
within minutes of energy loss, and then progress after hours and
days following the insult culminating in inflammatory events, cell
injury and tissue death [3]. Some of these mechanisms could be
targets for neuroprotective therapies aimed to prevent neuronal
damage [4].
n-3 triglycerides (TG) are studied here as a potential stroke
treatment as there are multiple cellular and metabolic functions
that are modulated by n-3 fatty acids (FA), especially docosahex-
aenoic acid (DHA), eicosapentaenoic acid (EPA), and their
biologically active derivatives that could play a role in neuropro-
tection from ischemic stroke [5]. n-3 FA are precursors to lipid
mediators that play an important role in regulating multiple
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pathways including regulation of cytokines, chemokines, and pro-
inflammatory signaling molecules [6]. n-3 FA are anti-inflamma-
tory, anti-apoptotic, and they decrease coagulation factors and
vascular resistance [6]. They also bind to transcription factors
affecting the regulation of genes [7]. These effects may contribute
to many ‘‘positive’’ roles that n-3 FA may play in human health,
including those in the areas of immune/inflammatory outcomes,
neurological degeneration, and cardiovascular disease [8].
Ischemic stroke triggers activation of phospholipase A2 (PLA2)
which stimulates the release of esterified FA from brain
membranes [9], and results in altering the FA content of specific
brain membrane phospholipid pools to play a role in tissue injury
[9]. In addition, released FA are enzymatically converted to anti-
inflammatory lipid messengers. For example, DHA is converted to
neuroprotectin D1 (NPD1) [9] which exhibits potent neuropro-
tective bioactivity after ischemic injury via protection from
oxidative stress induced apoptosis and anti-inflammatory path-
ways. However, when the ischemic insult is severe, endogenous
protection mechanisms are not enough to protect the brain from
inflammation and the ensuing damaging pathways [10]. Exoge-
nous administration (continuous infusion) of DHA bound to
human albumin has been previously shown to be neuroprotective
in an adult rodent stroke model [11]. However, albumin at high
dose expands intravascular volume and may precipitate congestive
heart failure, but with concomitant NPD1 synthesis in the
ipsilateral side after stroke [11]. Also, direct infusion of free FA
at high doses can lead to encephalopathy and hepatotoxicity [12].
Thus, in the present study we utilized acute administration of n-3
rich TG emulsions that allows for slower release of n-3 FA [13,14].
The brain’s response to hypoxia-ischemia or stroke is age-
dependent both in the degree and timing of apoptosis and in the
inflammatory response [15,16]. We have studied hypoxic-ischemic
(H/I) brain injury in neonatal mice using an H/I model well
established in our laboratories [17]. Our results demonstrate that,
in developing H/I brain, acute administration of n-3 TG up to
2 hr after H/I insult is protective against H/I-induced brain
injury. Specifically, tridocosahexaenoic acid (Tri-DHA), but not
trieicosapentaenoic acid (Tri-EPA), has a major role in early
neuroprotection after acute H/I brain injury.
Materials and Methods
Ethics Statement
All research studies were carried out according to protocols
approved by the Columbia University Institutional Animal Care
and Use Committee (IACUC) and in accordance with the
Association for Assessment and Accreditation of Laboratory
Animal Care guidelines.
Materials
Tri-DHA and Tri-EPA were purchased from Nu-Chek Prep,
Inc. (Elysian, MN). Egg yolk phosphatidylcholine was obtained
from Avanti Polar-Lipids, Inc. (Alabaster, AL).
Lipid Emulsions
Four different types of lipid emulsions were used in our
experiments. n-3 fish oil-based and n-6 soy oil-based emulsions
were commercially prepared intravenous phospholipid-stabilized
emulsions, and n-3 TG contained high concentrations of n-3 FA as
previously described (Table S1) [13,18]. In the text and Figure
Legends these are referred to as n-3 TG and n-6 TG emulsions.
The n-6 TG emulsions were produced from soy bean oil rich in n-
6 FA: linoleic acid constituting about 55% of total FA. In contrast,
the n-3 TG emulsions, which contained fish oil, were rich in EPA
(up to 28%) and DHA (up to 30%). For doses of injected n-3 TG
emulsions, we calculated that the amount adiministered contains
50% of the TG–FA as DHA and EPA (Table S1). Thus, 1 gm of
TG emulsions is expressed as 0.5 gm n-3 TG.
The pure Tri-DHA and Tri-EPA emulsions were VLDL-sized
and laboratory-made with TG oil and egg yolk phospholipid using
sonication and centrifugation procedures that we have previously
detailed [19–21]. Briefly, 200 mg Tri-DHA (Tri-DHA oil .99%)
or Tri-EPA (Tri-EPA oil.99%) was mixed with a 5:1 weight ratio
of egg yolk phosphatidylcholine (40 mg). The mixture was fully
evaporated under N2 gas, and was further desiccated under
vacuum overnight at 4uC. The dried lipids were resuspended in
1 mL of lipoprotein-free buffer (LPB) (150 mmol/L NaCl, 0.5 ml
of 0.1% glycerol and 0.24 mmol/L EDTA, pH 8.4, density
1.006 g/mL) at 60uC with added sucrose (100 mg/1 mL LPB) to
remove excess phospholipid liposomes. The lipid emulsions were
then sonicated for 1 hr at 50uC, 140 W under a stream of N2 using
a Branson Sonifier model 450 (Branson Scientific, Melville, NY).
After sonication, the solution was dialyzed in LPB for 24 hr at 4uC
to remove sucrose. The final emulsions comprising VLDL-sized
particles were analyzed for the amount of TG and PL by
enzymatic procedure using GPO-HMMPS, glycerol blanking
method (Wako Chemicals USA, Inc., Richmond, VA) and choline
oxidase-DAOS method (Wako Chemicals USA, Inc., Richmond,
VA). The TG: phospholipid mass ratio was 5.061.0:1 similar to
that of VLDL-sized particles. The emulsions were then stored
under argon at 4uC and were used for experiments within 2 weeks
of preparation.
Unilateral Cerebral H/I
Three-day-old C57BL/6J neonatal mice of both genders were
purchased from Jackson Laboratories (Bar Harbor, ME) with their
birth mother. We used the Rice-Vannucci model of H/I modified
to p10 neonatal mice [17]. Briefly, on postnatal day 10 H/I was
induced by the ligation of the right common carotid artery, which
was further cauterized and cut under isoflurane anesthesia. The
person who performed the procedure was blinded to the lipid
emulsion treatment during the surgery and after the surgery. The
entire surgical procedure was completed within 5 min for each
mouse. Pups were then allowed to recover with their dams for
1.5 hr. Surrounding temperature during experiments was kept at
28uC. Mice were then exposed to systemic hypoxia for 15 min in a
hypoxic chamber in a neonatal isolette (humidified 8% oxygen/
nitrogen, Tech Air Inc., White Plains, NY) [17]. The ambient
temperature inside the chamber during hypoxia was stabilized at
3760.3uC. To minimize a temperature-related variability in the
extent of the brain damage, during the initial 15 hr of reperfusion
mice were kept in an isolette at the ambient temperature of 32uC.
Quantification of Brain Infarction
After 24 hr of reperfusion, the animals were sacrificed by
decapitation and brains were immediately harvested. 1-mm
coronal slices were cut by using a brain slicer matrix. Slices were
then immersed in a PBS solution containing 2% triphenyl-
tetrazolium chloride (TTC) at 37uC for 25 min. TTC is taken up
into living mitochondria, which converts it to a red color [22].
Thus, viable tissue stains brick-red, and nonviable (infarcted) tissue
can be identified by the absence of staining (white). Using Adobe
Photoshop and NIH Image J imaging applications, planar areas of
infarction on serial sections were summed to obtain the volume
(mm3) of infarcted tissue, which was divided by the total
(infarcted+non-infarcted) volume of the hemisphere ipsilateral to
carotid artery ligation, and expressed as a percentage of total
volume.
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Experimental Groups
H/I brain injury was induced in different groups of animals,
which received specific treatments before and after H/I injury.
Animals followed the following treatment protocols.
i) Pre-H/I treatment of n-3 TG (containing both DHA and
EPA) or n-6 TG emulsions. Two doses of n-3 TG or n-6 TG
emulsions or vehicle (saline, equal volumes/kg) were admin-
istered to non-fasting rodents at a fixed dose of 3 mg of n-3 or
n-6 TG-FA per mouse for each injection (equivalent to a
maximum of 1.5 g of total TG/kg; p10 mice weighed 4–6 gm
for these experiments). The first dose was intraperitoneally
(i.p.) administered immediately after surgery, and the second
immediately at the end of the 15 min hypoxic period.
Volumes injected for TG emulsions and saline were always
equal.
Since n-3 emulsions contain low concentrations of alpha-
tocopherol as an anti-oxidant agent, in separate experiments an
equivalent dose of pure alpha-tocopherol to match the content of
n-3 emulsion content (0.8 g/L) was given to neonatal mice by i.p.
injection of alpha-tocopherol (Vital EH, Intervet, Schering Plough)
at a dose of 5 mg alpha-tocopherol/kg body weight, the amount
contained in each i.p. injection of the n-3 TG emulsions.
ii) Post-H/I treatment of n-3 TG (containing both DHA
and EPA). Two doses of the commercially available n-3 TG
emulsion or saline were i.p. injected into non-fasting rodents
at 0.75 g of n-3 TG/kg body weight for each dose (equivalent
to 1.5 g of total TG/kg). The first dose was administered
immediately after 15-min hypoxia, and the second at 1 hr
after start of the reperfusion period.
iii) Dose response, timing and specificity of n-3 TG. Two
types of n-3 containing lipid emulsions either Tri-DHA or
Tri-EPA (0.1 g n-3 TG/kg or 0.375 g n-3 TG/kg body
weight for each dose) were administered twice to non-fasting
rodents (according to the amount of DHA and EPA in the
mixed n-3 TG emulsions) (Table S1). The first dose was
initially administered immediately after 15-min hypoxia, and
the second after 1 hr of reperfusion. Then in different sets of
experiments, we determined the efficacy of Tri-DHA
emulsions, with the initial injection administered at four-time
points (0 hr, or at 1-hr, 2-hr or 4-hr after H/I), 0.375 g n-
3 TG/kg body weight for each dose. For the immediate
treatment of 0 hr, the first dose was injected immediately after
15-min hypoxia, with a second injection after 1 hr of
reperfusion, whereas in the ‘‘delayed’’ treatments, the first
dose was given after the 1st or 2nd or 4th hr of reperfusion and
a second dose was administered 1 hr after the 1st dose.
Blood TG and Glucose Levels
Blood samples for blood TG were directly taken from left
ventricle of hearts under isoflurane inhalation from a separate
cohort of non-fasting, 10-day-old mice. Samples were taken over a
5 hr period after a single i.p. injection of either 0.75 g n-3 TG/kg
commercially available n-3 rich TG (DHA and EPA) emulsions or
saline. Total plasma TG was enzymatically measured by GPO-
HMMPS, glycerol blanking method (Wako Chemicals USA, Inc.,
Richmond, VA). For glucose levels, blood samples were taken
from mouse tails from a separate cohort of non-fasting10-day-old
mice. Samples were taken at two time points from each mouse.
The first sample was taken at time zero before surgery and TG
injection, and the second at about 10 min after H/I and TG
injection (approximately 100 min after surgery as described under
the Unilateral Cerebral H/I protocol above). Blood glucose levels
were electrochemically measured in mg/dL by a glucose meter
(OneTouch Ultra, LifeScan, Inc., Milpitas, CA).
Cerebral Blood Flow (CBF) by Laser Doppler Flowmetry
(LDF)
In a cohort of neonatal C57BL/6J mice pups subjected to
carotid artery ligation and recovery as described above, relative
CBF was measured during hypoxia in ipsilateral (right) hemi-
spheres using a laser Doppler flowmeter (Periflux 5000). In these
mice, in preparation for CBF measurement the scalp was dissected
under isoflurane anesthesia and Doppler probes were attached to
the skull (2 mm posterior and 2 mm lateral to the bregma) using
fiber optic extensions. Only local anesthesia (1% lidocaine) was
used postoperatively. Mice were then placed into a hypoxia
chamber (8%O2/92%N2). Changes in CBF in response to hypoxia
were recorded for 20 min and expressed as percentage of the pre-
hypoxia level for n-3 treated and saline treated neonatal mice.
Bleeding Time after n-3 TG Injection
Bleeding times were measured in mice after severing a 3-mm
segment of the tail (as previously described) [23]. We gave two
doses of saline vs. n-3 TG in a similar time frame as the original
protocol: an initial injection followed by a second injection at 2 hr
later. Bleeding times were measured at 45 min after the second
dose. The amputated tail was immersed in 0.9% isotonic saline at
37uC, and the time required for the stream of blood to stop was
defined as the bleeding time. If no cessation of bleeding occurred
after 10 min, the tail was cauterized and 600 s was recorded as the
bleeding time.
Long-term Assessment of Brain Tissue Death
A long-term assessment of cerebral injury was performed at
8 wk after neonatal H/I insult. This cohort of mice at p10
underwent unilateral H/I followed by post H/I injections with
either 0.375 g Tri-DHA/kg (n = 6) or saline (n = 5) as described
above. At 8 wk after H/I mice were sacrificed by decapitation.
Brains were removed, and embeded in Tissue Tek-OTC-compound
(Sakura Fineteck, Torrance, CA) with subsequent snap freezing in
dry ice-chilled isopentane (230uC), and stored at 280uC. For
analysis, coronal sections (10 mm every 500 mm) were cut serially
in a Leica cryostat and mounted on Superfrost slides (Thermo
Scientific, Illinois). Sections were processed for Nissl staining by
using Cresyl Violet Acetate (Sigma-Aldrich, St. Louis, MO). Using
Adobe Photoshop and NIH Image J imaging applications, 9
sections from each brain containing both the right and left
hemispheres were traced for brain tissue area. As previously
described [24] the area of left control or contralateral hemisphere
which had not had injury was given a value in 100% for each
animal. The brain area remaining in the right injured ipsilateral
hemisphere was then compared to the left hemisphere, and the
difference was taken as the percent right brain tissue loss, for each
animal.
Statistical Analyses
Data are presented as mean 6 SEM. We compared plasma TG
levels at each time point after i.p. injection of n-3 TG emulsion.
Student t tests were used for 2-group comparisons. 1-way
ANOVA, followed by Bonferroni procedure for post hoc analysis
to correct for multiple comparisons, was used to compare the
differences among the emulsions on the infarct areas across
coronal sections. Statistical significance, which was analyzed by
N-3 Triglycerides and Acute Stroke Neuroprotection
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using SPSS software 16.0 (SPSS Inc., Chicago, IL), was
determined at p,0.05.
Results
Effects of n-3 TG on Blood Triglyceride and Glucose
Levels, and Bleeding Time
To determine if TG from the n-3 TG emulsions were
systemically absorbed, we examined the blood TG levels up to
5 hr after i.p. injection. After n-3 TG injection, there was a
substantial increase of TG levels up to three fold higher at 1.5 hr
(p,0.05) compared to the baseline, followed by a decrease of levels
to baseline at 3 and 5 hr (Figure 1A). This indicates that n-3 TG
had entered into the blood stream and were being catabolized. In
comparison, TG levels of saline-injected mice remained constant
over the 5 hr time period reflecting normal blood TG levels in
neonates.
After H/I, blood glucose levels might affect infarct size [25].
Therefore, we measured blood glucose levels in each group (n-3
TG vs. n-6 TG vs. saline control) prior to surgery and after 15-min
H/I after TG or saline injection (Figure 1B). No difference in
blood glucose levels among groups was observed when comparing
at the same time point. Still, after H/I insult, blood glucose levels
decreased similarly, about 30% or more, in all groups (p,0.05).
There was no difference in capillary bleeding times in n-3
treated mice (437682 sec) as compared to saline controls
(418690 sec).
n-3 TG does not Change Cerebral Blood Flow after H/I
There was no effect on CBF in the ipsilateral hemisphere of n-3
treated neonatal mice as compared to saline treated animals.
Immediately after right common carotid artery ligation, and
initiation of hypoxia at 8% oxygen, CBF was approximately 25%
of initial (pre-H/I) level in the ipsilateral hemisphere in both
control and n-3 treated groups, and this was maintained for the
duration of hypoxia. In the contralateral (unligated) hemisphere
blood flow was unchanged in both groups. Very similar blood flow
levels were maintained in neonatal H/I mice whether they were
saline treated or n-3 treated in this model (Figure 2).
n-3 TG but not n-6 TG Protects Brain against H/I Injury
Coronal sections of brains were stained with TTC to quantify
the extent of post H/I brain injury and the effect of n-3 TG
injection (Figure 3). Figure 3A shows representative images of
neonatal mouse brain from saline treated, n-6 TG emulsion
treated and n-3 TG emulsion treated mice with pre-and-post
injection after H/I, respectively. In all H/I animals, tissue death
was localized to the right hemisphere (ipsilateral to ligation) as
illustrated by the white areas in the upper panels of Figure 3A. The
image in the lower panels, Figure 3A, demonstrates tracings of the
infarcted areas for quantifying infarct volume using NIH Image J.
The brains from saline treated animals exhibited a consistent
pannecrotic lesion involving both cortical and subcortical regions
ipsilateral to the ligation. In the majority of the animals the
neuroprotection after n-3 TG injection was most marked in the
subcortical area, whereas saline treated mice had large cortical and
subcortical infarcts (Figure 3A).
Infarct volume was substantially decreased in n-3 TG treated
mice (n = 28) compared to saline treated littermates (control)
(n = 27), 19.964.4% vs. 35.165.1%, respectively (p = 0.02)
(Figure 3B). There was a significant increase in infarct volume
with n-6 TG emulsion injection compared to saline control
(p = 0.03) and the n-3 TG groups (p,0.01).
Because alpha-tocopherol is a component of the TG emulsions
(present in low concentrations to prevent FA oxidation) we also
used TTC staining to compare the extent of cerebral H/I injury in
alpha-tocopherol treated and saline treated neonatal mice. There
was no significant difference in infarct volume between brains in
alpha-tocopherol injected mice compared to saline treated mice
(data not shown).
We next determined if n-3 TG are effective if injected only after
H/I (without injection prior to H/I (Figure 3C)). Similarly, the
smaller n-3 TG associated lesions were mainly subcortical (data
not shown). Compared to saline controls in the immediate post-H/
I treatment the total infarct area was significantly reduced almost
50% in the n-3 TG post H/I treated group.
DHA but not EPA is Neuroprotective after H/I
To determine possible differences in neuroprotection of EPA vs.
DHA, we studied the extent of brain injury using the post-H/I
treatment protocol with Tri-DHA vs. Tri-EPA in two dosages
(0.1 g TG/kg vs. 0.375 g TG/kg). No statistical differences in
brain infarct volume between 0.1 g TG/kg and 0.375 g TG/kg
Tri-DHA treated groups were observed. However, compared to
saline control, total infarct size was reduced by a mean of 48% and
55% by treatment with 0.1 and 0.375 g TG/kg Tri-DHA,
respectively (Figure 4). Neuroprotection was not observed with
Tri-EPA injection at either of the two doses compared with saline
treatment.
To better approximate realistic timelines for neuroprotection
after stroke for humans we performed delayed treatment protocols
to study the therapeutic window of Tri-DHA emulsions. No
protective effect from Tri-DHA after a 4-hr delay in treatment was
noted compared with saline group. However, Tri-DHA adminis-
tered at 0 hr immediately post H/I, and then delayed 1-hr and 2-
hr post stroke showed similar reduced (, 50%) brain infarct
volumes compared to saline treated animals (Figure 5). This
substantial protection occurred mainly in subcortical areas similar
to the findings described above.
Long-term Neuroprotection
Coronal brain sections of adult mice were processed for Nissl
staining (Figure 6) to examine the effects of H/I and Tri-DHA
treatment on brain and neuronal cell loss for long-term outcome at
8 wk after H/I insult. As compared to the left control (contralat-
eral hemisphere), the injured areas of the right hemisphere display
gross neuronal cell loss. As shown in Figure 6, brain tissue loss was
markedly increased by 1.67 fold in the right hemisphere of saline-
treated mice (n = 5) as compared to Tri-DHA treated mice (n = 6),
25.062.4% vs. 15.062.5%, respectively (p = 0.02). Thus, neuro-
protection after injury and Tri-DHA injection that are observed
24 hr after H/I can be demonstrated histologically almost 2
months after the initial stroke insult.
Discussion
We questioned whether acute administration of n-3 TG would
provide neuroprotection in neonatal H/I brain injury and sought
to determine the specificity of different TG in protecting brain
tissue. Cerebral ischemic injury (stroke) is a serious problem in all
periods of the life cycle. We chose to focus on the neonatal mouse
model, not only because stroke is an important problem in the
neonatal period in humans, but also because underlying mecha-
nisms of H/I are well studied in this model [17,26–28]. There was
significant neuroprotection by n-3 TG in this model. In all
experiments, ischemic injury is localized to the hemisphere
ipsilateral to ligation and was characterized by infarction and
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neuronal tissue loss. Also, n-3 treatment decreased brain injury by
attenuating tissue injury in multiple regions of the brain.
Somewhat surprisingly, we found that these neuroprotective
effects were limited to TG-enriched only in DHA, but not EPA.
Also, neuroprotection was evident when n-3 TG were injected
2 hr after the H/I injury.
It is well recognized that TG composition of n-3 lipid emulsions
affects blood clearance catabolism and tissue uptake [19,29]. This
study demonstrated that n-3-rich TG emulsions are also system-
ically absorbed after i.p. injection, and can substantially raise
blood TG levels within short time periods, which in our
experiment peaked at 1.5 hr post injection. The emulsion was
efficiently catabolized as evidenced from blood TG levels dropping
to baseline levels within 3 hr. Still, experiments with more time
points after n-3 TG injection would be informative.
We first questioned whether acute administration of n-3 TG
would provide neuroprotection at fixed doses of n-3 TG in our
model of 10-day-old mice. The experimental doses were consistent
with doses of intravenous lipid emulsions in human neonates at 1–
1.5 g total TG/kg/day (0.5–0.75 g n-3 TG/kg). We initially
demonstrated that n-3 TG, when administered in a ‘‘preventive’’
approach (pre-H/I treatment protocol), attenuated cerebral injury
by reducing cerebral infarction in keeping with results from
Berman [27] and Pan [30] in different neonatal and adult rat
DHA protocols using pre-event i.p. administration, indicating that
pretreatment with n-3 TG confers positive neuroprotection from
brain H/I. Our preliminary data in pre-H/I treatment protocols
also showed similar levels of neuroprotection by n-3 TG in adult
mouse and rat brain H/I injury models [28]. The effects of the age
disparity between the models utilized, such as varied substrate
Figure 1. Blood TG and glucose levels after TG emulsion injections. A. Total plasma TG concentrations (mg/dL) in non-fasting neonatal mice
(p10), acutely injected (i.p.) with saline or n-3 TG emulsion (0.75 g n-3 TG/kg body weight). *p,0.05 (n = 3–8 in each group). Each data point
represents the mean 6 SEM of 3 separate experiments. B. Plasma glucose concentrations (mg/dL) in non-fasting mice (p10) in post-H/I treatment of
n-3 TG or n-6 TG or vehicle (saline) comparing to the time between before H/I and after H/I. **p,0.001 (n = 5–9 in each group).
doi:10.1371/journal.pone.0056233.g001
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utilization in the developing brain, and potential differences in
cerebral vasculature [31,32], are differences that could have an
effect on mechanisms of neuroprotection. However, even with
these potential differences we still observed the neuroprotective
effect from n-3 treatment. In each case, ischemic injury was
localized to the right hemisphere ipsilateral to ligation and was
characterized by infarction, neuronal tissue loss and an increase in
degenerating neurons. n-3 TG treatment decreased brain injury
by attenuating tissue injury in multiple regions of the right brain
[28].
We demonstrated that when administered in a more ‘‘thera-
peutic’’ approach i.e., in post-H/I only treatment protocols, n-3
TG attenuated cerebral injury by reducing cerebral infarction size,
indicating that post-H/I treatment with n-3 TG confers positive
neuroprotection from brain H/I. Another question is whether
neuroprotective effects seen here are a result of the combined
effects of EPA and DHA contained in the emulsion, or related
more to one of these FA; we used laboratory-made Tri-DHA or
Tri-EPA emulsions to address this. We found that acute post-H/I
treatment with Tri-DHA, at a lower dose (0.1 g n-3 TG/kg/dose)
and higher dose (0.375 g n-3 TG/kg/dose), both resulted in
decreased cerebral infarct volumes, with protection most marked
in the subcortical regions of the brain tissue. Interestingly, no
protection was observed after Tri-EPA injection (Figure 4). In
studies of the long-term consequences of the H/I insult, we found
that Tri-DHA showed cerebral neuroprotection 8 wk after injury
with much less cerebral volume loss.
In clinical studies, it was shown that DHA and EPA have TG
lowering effects [33]. However, in animal models of cerebrovas-
cular diseases such as stroke and myocardial infarction, DHA
appears to confer more promising organ protection than does EPA
[30,34,35]. Underlying mechanisms for these differences need to
be determined. Our preliminary data [28] indicates that neuro-
protective effects of the n-3 TG emulsions in our model are likely
related, in part, to NPD1, a potent derivative docosanoid of DHA.
Endogenous response to H/I is also associated with an elevation of
NPD1 in saline treated adult mice [36]. These results demonstrate
that ischemic injury activates the cascade of events that lead to
increased production of NPD1. In our preliminary studies in adult
mice [28], post-ischemic elevation of NPD1 was significantly
enhanced by the administration of an n-3 rich TG emulsion
containing DHA and EPA (data not shown). As a result, we
suggest that the n-3 TG emulsions might add to the existing
reservoir of n-3 FA, in brain or other organs and that the enzyme
systems activated by ischemia in H/I mice catalyze two pools of
DHA substrate - the endogenous DHA liberated from the
phospholipid membrane and exogenous DHA from the n-3 TG
emulsion. AA derived lipid messengers 12(S) HETE, 15(S) HETE,
and lipoxin A4 were also measured in whole brain from saline
treated adult mice and n-3 TG treated mice (data not shown).
These latter preliminary measurements were made because in
addition to liberation of DHA from the phospholipid membrane in
response to H/I, AA is also liberated by PLA2 and could have
potentially led to elevated levels of its metabolites. However, there
were no differences between groups for any of these metabolites
(data now shown), in support of the hypothesis that the increased
NPD1 levels are likely related to the DHA in the administered n-3
TG emulsion. As NPD1 attenuates classical features of inflamma-
tion, and protects cells from oxidative stress-induced apoptosis
[37], it is likely that the neuroprotective effects of n-3 FA in our
neonatal models also involve NPD1’s effects on these pathways.
Nevertheless, to gain deeper understanding of the effects of NPD1
in our model it will be important to study the downstream
mechanisms affected by NPD1 such as decreased polymorphonu-
clear leukocytes infiltration, and effects on apoptotic gene signaling
as NPD1 has been shown to inhibit leukocyte infiltration [38] and
apoptosis [39] in other models.
The timing of the administration of n-3 TG may be of
significance as the various mechanisms involved in H/I injury
occur over a wide time span, from the initial minutes to several
days following the ischemic insult [3]. We examined whether
DHA could still confer neuroprotection in H/I brain injury in the
case of delayed treatment after H/I insult. In our n-3 TG dose-
response experiment, both the low dose and the high dose of DHA
were neuroprotective in reducing infarct volume when adminis-
tered immediately after H/I insult. Again, the neuroprotective
effect of DHA was demonstrated mostly in the subcortical region
(penumbra area) by very substantial reductions in cerebral infarct
volume when first administered at 0 h, 1 h and 2 hr after injury,
respectively. Our findings are consistent with a study of Belayev
Figure 2. n-3 TG injection and cerebral blood flow after H/I. Cerebral blood flow (CBF) was measured by laser Doppler flowmetry (LDF) in
neonatal mice after carotid artery ligation. Relative CBF was measured every two minutes during hypoxia in ipsilateral (right) hemispheres using a
laser Doppler flowmeter. Changes in CBF in response to hypoxia were recorded for 20 min and expressed as percentage of the pre-hypoxia level for
n-3 TG treated (n = 3) and saline treated (n = 5) neonatal mice.
doi:10.1371/journal.pone.0056233.g002
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[40] using an adult rat model where delayed treatment with DHA
conferred neuroprotection. Their findings showed that DHA
treatment could be delayed up to 5 hr after the stroke onset,
different than our finding in neonatal mice where we did not
observe neuroprotection 4 hr after H/I. This may be related to
differences in the pathways of stroke progression in adult vs.
neonate rodents, as well as possible differences in the mechanisms
of neuroprotection.
Of special note, differences in metabolic rate may play a major
role in defining the rapidity of apoptotic responses in mice vs.
humans. Theoretical estimation indicates that the energy expen-
diture per kg in different size mammals is inversely proportional to
body weight [41]. On this basis, it was assumed that metabolic rate
and energy utilization per kg body weight in mice is 7 times higher
in mice than in humans [42,43]. Therefore, two hours in delay
treatment in our protocol may represent substantially longer time
Figure 3. TTC stained coronal sections of mouse brain and quantification of injury after H/I. A. TTC-stained coronal sections of
representative mouse brains from saline treated, n-3 TG treated and n-6 TG treated. The top panel shows images of coronal mouse brain that are
sliced and then stained with TTC (grey for living tissue and white for the infarcted tissue), and the lower panel shows the infarcted areas that are
traced in black for quantification. B. Percent of cerebral infarct volume from pre-H/I mice treated with n-3 TG emulsion (n = 28) or n-6 TG emulsion
(n = 10) or saline control (n = 27). C. Percent of cerebral infarct volume after H/I in the post-H/I treatment protocol in mice treated with n-3 TG
emulsion (n = 18) or saline control (n = 18). Each bar represents the mean 6 SEM of 5–7 independent experiments.
doi:10.1371/journal.pone.0056233.g003
Figure 4. Effect of Tri-DHA versus Tri-EPA on cerebral infarct volume after H/I. A. Mice were subjected to 15 min ischemia followed by 24-
hr reperfusion and received 2 i.p. administrations (immediately after ischemia and 1 hr of reperfusion) at 2 doses (0.1 g n-3 TG/kg and 0.375 g n-
3 TG/kg). Each bar represents the mean 6 SEM of 5–7 independent experiments performed using the same H/I model. B. TTC-stained coronal
sections of representative mouse brains from saline treated, 0.1 g Tri-DHA, 0.375 g Tri-DHA, 0.1 g Tri-EPA and 0.375 g Tri-EPA. * p,0.05 compared to
other groups except 0.1 g Tri-DHA/kg. ** p,0.05 compared to other groups except 0.375 g Tri-DHA/kg and 0.375 g Tri-EPA/kg.
doi:10.1371/journal.pone.0056233.g004
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‘‘windows’’ in terms of new therapeutic approaches for stroke in
humans with n-3 TG emulsions.
The aim of some therapeutic treatments, in large part, remains
focused on reperfusion to the area of infarct plus symptom relief
[44–47]. An initial insult in ischemic stroke is a reduction in CBF
[5,48]. The duration and intensity of the blood flow deficit are
associated with the severity of brain damage. We measured CBF
during hypoxia to determine the effect of n-3 FA treatment in
neonatal mice. However, we found that there were no differences
in CBF between n-3 TG treated and saline treated neonatal mice
after H/I, indicating that other mechanisms are involved in our
experiments.
Also, it is very unlikely that the extra energy supply of n-3 TG
emulsions had any effects on neuroprotection. n-3 TG and n-6
TG emulsions injected had similar caloric densities, but as seen
in Figure 3, n-3 TG provided neuroprotection but n-6 TG did
not.
Our results provide new insights into the potential of
employing n-3 TG, specifically DHA as a unique long chain
FA aiding in neonatal H/I brain injury. A number of pathways
are likely involved in n-3 TG neuroprotection [5]. For example,
chronic administration of DHA resulted in increases of DHA
levels in brain mitochondria. Increasing DHA might induce
anti-apoptotic Bcl-2 proteins and inhibit apoptotic Bcl-2
proteins as well as improve mitochondrial capacity to handle
excessive intracellular Ca2+ concentrations after H/I insult
[5,30].
Also, reperfusion injury after H/I is now well-known as a cause
of the generation of oxidative radicals and the release of pro-
apoptotic proteins contributing to the cellular damage [49].
Interactions among multiple interrelated mechanisms need to be
addressed in order to improve cell survival, thereby reducing
morbidity and mortality. The data from Belayev [40] in a post-
stroke protocol indicate that DHA treatment not only protects
both neurons and astrocytes, but also attenuates microglia
activation, which leads to the initiation of apoptotic cascades. In
ongoing and in preliminary experiments after H/I in neonatal
mice we have found that injection of n-3 TG lipid emulsion
reduced reactive oxygen species (ROS) production in whole brain,
and this was associated with markedly reduced emission of ROS
from mitochondria assessed at 30–60 min after initiation of
reperfusion [50].
Figure 5. Effects of delayed treatment with Tri-DHA on cerebral infarct volume after H/I. Mice were subjected to 15-min ischemia
followed by 24-hr reperfusion and received 2 i.p. administrations at four-time points (immediate [0,1 hr], delayed 1-hr [1,2 hr], or 2-hr [2,3 hr] or 4-hr
[4,5 hr] treatments). Each bar represents the mean6 SEM of 5–7 independent experiments. * p,0.05; ** p,0.001 vs. saline control (n = 10–20 in each
group).
doi:10.1371/journal.pone.0056233.g005
Figure 6. Long-term effect of Tri-DHA on cerebral tissue death
at 8 wk after H/I. Mice were subjected to 15-min H/I and received 2
i.p. administrations of 0.375 g Tri-DHA/kg (n = 6) vs. saline (n = 5). At
8 wk after H/I mice were sacrificed and brains were fixed with 4%
paraformaldehyde and 10 mm-thick slices were cut and preserved. Nissl
staining was used for identifying neuronal and brain structure. As
described in Methods right brain tissue loss in relation to the
contralateral hemisphere was calculated and expressed as a percent-
age. Each bar represents the mean 6 SEM. * p,0.05.
doi:10.1371/journal.pone.0056233.g006
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n-3 FA have been found to be safe and effective in the
treatment of other neurological injuries including spinal cord
injury [51–53]. Of interest both EPA and DHA showed
neuroprotection after spinal cord injury [51,52]. Reasons for
lack of effect of Tri-EPA in our studies remain to be
determined.
Our findings suggest a need for further studies to determine if
acute injection of n-3 TG could be neuroprotective after stroke
injury in humans. We also hypothesize that n-3 FA in TG,
specifically DHA, will prove to be a ‘‘novel’’ and important
therapy to treat stroke and could decrease mortality and increase
long-term functional recovery after stroke in humans of different
ages.
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